Evidence map›Paper›PMID 39540965›Full record

ArticleArchives of microbiology2024

Construction of engineered probiotic that adhere and display nanobody to neutralize porcine reproductive and respiratory syndrome virus.

Li Zhou, Hanlin Zhou, Panying Wang, Hang Xu, Jiayi Wu, Yuanzhuo Zhou, Jiaying Feng, Weiyi Zheng

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of microbiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Nanobodies in animal infectious disease control: diagnosis and therapy.Frontiers in cellular and infection microbiology · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Li ZhouSchool of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, P. R. China.
Hanlin ZhouCollege of Life Science and Technology, Mudanjiang Normal University, 191 Wenhua Street, Mudanjiang, 157011, China.
Panying WangSchool of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, P. R. China.
Hang XuState Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Affiliated to Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200120, P. R. China.
Jiayi WuSchool of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, P. R. China.
Yuanzhuo ZhouSchool of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, P. R. China.
Jiaying FengSchool of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, P. R. China.
Weiyi ZhengSchool of Food Science and Pharmaceutical Engineering, Nanjing Normal University, Nanjing, 210023, P. R. China. 77043@njnu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pathogenic blue ear disease caused by porcine reproductive and respiratory syndrome virus (PRRSV) bring severe loss to breeding industry due to high infectivity and mortality. L. plantarum serves as the probiotic host strain, known for its beneficial properties in the gut microbiota. E. coli is used as a cloning host for the initial genetic engineering steps, facilitating the construction and amplification of the desired genetic constructs. In this study, using synthetic biology technology, we constructed engineered probiotics which could adhere and display nanobody on the surface to neutralize virus. Firstly, we screen an optimal nanobody to effectively bind with PRRSV by building library, expression and purification. Then, the integration of adhesion protein and nanobody into the genome of probiotics significantly improved its adhesion to IPEC-J2 cells. In addition, this engineered probiotic is almost non-toxic to cells with good safety, which can be used as a daily probiotics to prevent virus fecal transmission. Our study proposed this novel construction strategy of engineering probiotics with both adhesion and neutralization effects, which provided a new therapeutic view for intestinal virus clearance.

Indexed as

Bacterial AdhesionPorcine respiratory and reproductive syndrome virusProbioticsSingle-Domain AntibodiesAnimalsCell LineEscherichia coliGenetic EngineeringLactiplantibacillus plantarumPorcine Reproductive and Respiratory SyndromeSwineSingle-Domain AntibodiesNanobodyPRRSVRecombinant bacteriaVirus neutralization

Identifiers

PMID39540965

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.